These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19240256)

  • 1. Sunitinib adverse event: oral bullous and lichenoid mucositis.
    Mignogna MD; Fortuna G; Leuci S; Pollio A; Ruoppo E
    Ann Pharmacother; 2009 Mar; 43(3):546-7. PubMed ID: 19240256
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
    Garfield D; Hercbergs A; Davis P
    Nat Clin Pract Oncol; 2007 Dec; 4(12):674. PubMed ID: 17955044
    [No Abstract]   [Full Text] [Related]  

  • 4. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.
    Suwattee P; Chow S; Berg BC; Warshaw EM
    Arch Dermatol; 2008 Jan; 144(1):123-5. PubMed ID: 18209189
    [No Abstract]   [Full Text] [Related]  

  • 5. Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases.
    Schellekens AF; Mulder SF; van Eijndhoven PF; Smilde TJ; van Herpen CM
    Gen Hosp Psychiatry; 2011; 33(1):83.e1-3. PubMed ID: 21353137
    [No Abstract]   [Full Text] [Related]  

  • 6. [Adverse effects of Sutent(®): pseudoporphyria and scrotal necrosis].
    Schmutz JL
    Ann Dermatol Venereol; 2014 Dec; 141(12):815-6. PubMed ID: 25433941
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
    J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Garfield DH; Hercbergs A; Davis PJ
    J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
    [No Abstract]   [Full Text] [Related]  

  • 9. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
    Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
    [No Abstract]   [Full Text] [Related]  

  • 10. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.
    Arnaud L; Schartz NE; Bousquet G; Sarandi F; Verola O; Madelaine I; Kerob D; Lebbe C
    J Clin Oncol; 2008 Mar; 26(9):1569-71. PubMed ID: 18349416
    [No Abstract]   [Full Text] [Related]  

  • 11. Sunitinib-induced hemoglobin changes are related to the dosing schedule.
    van der Veldt AA; Boven E; Vroling L; Broxterman HJ; van den Eertwegh AJ; Haanen JG
    J Clin Oncol; 2009 Mar; 27(8):1339-40; author reply 1340-2. PubMed ID: 19188672
    [No Abstract]   [Full Text] [Related]  

  • 12. Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs.
    Prescrire Int; 2009 Aug; 18(102):165. PubMed ID: 19746526
    [No Abstract]   [Full Text] [Related]  

  • 13. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
    Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
    Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):129-41. PubMed ID: 25482593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.
    Hoefert S; Eufinger H
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):463-9. PubMed ID: 20692189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
    Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
    Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
    Togo Y; Shimatani K; Hanasaki T; Yo T; Nakanishi Y; Nagasawa S; Hashimoto T; Shiraishi Y; Taoka R; Suzuki T; Go S; Higuchi Y; Kanematsu A; Nojima M; Tsuchihashi K; Makino Y; Shimizu Y; Kanamaru S; Kono Y; Matsumoto K; Utsunomiya N; Ito N; Kawakita M; Yamamoto S
    Hinyokika Kiyo; 2014 May; 60(5):209-14. PubMed ID: 24894855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.
    Zhou A
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):132-44. PubMed ID: 22524572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interactions with sunitinib.
    Bilbao-Meseguer I; Jose BS; Lopez-Gimenez LR; Gil MA; Serrano L; Castaño M; Sautua S; Basagoiti AD; Belaustegui A; Baza B; Baskaran Z; Bustinza A
    J Oncol Pharm Pract; 2015 Feb; 21(1):52-66. PubMed ID: 24403097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.